Carvedilol and Ivabradine

Interactions

Carvedilol and Ivabradine interacts in the following cases:

Renal impairment

No dosage adjustment is required in patients with renal insufficiency and creatinine clearance above 15 mL/min and SBP >100 mmHg.

No data are available in patients with creatinine clearance below 15 mL/min. Carvedilol/ivabradine should be used with precaution in patients with creatinine clearance below 15 mL/min.

Monitoring of renal function is recommended in chronic heart failure patients with SBP <100 mmHg.

Mild hepatic impairment, moderate hepatic impairment

It may be necessary to adjust the dose in patients with mild to moderate hepatic impairment.

Caution should be exercised in patients with moderate hepatic impairment.

Pregnancy

Based on existing data with the individual components, the use of carvedilol/ivabradine fixed-dose combination is contraindicated during pregnancy.

There are insufficient data on the use of carvedilol in pregnant women. Experimental animal studies have shown reproductive toxicity. The potential risk use in humans is unknown. Beta-blockers reduce placental perfusion which may result in intrauterine foetal death and immature and premature deliveries. In addition, adverse effects (especially hypoglycaemia and bradycardia, hypotension, respiratory depression and hypothermia) may occur in the foetus and neonate. There may be an increased risk of cardiac and pulmonary complications in the neonate during the postnatal period. There are no or limited amount of data from the use of ivabradine in pregnant women.

Animal studies with ivabradine have shown reproductive toxicity. These studies have shown embryotoxic and teratogenic effects. The potential risk for humans is unknown.

Nursing mothers

Carvedilol/ivabradine combination is contraindicated during breast-feeding.

Animal studies have shown that carvedilol or its metabolites are excreted in the breast milk. It is not known whether carvedilol is excreted in the human breast milk.

Animal studies indicate that ivabradine is excreted in milk. Women that need treatment with ivabradine should stop breast-feeding and choose for another way of feeding their child.

Carcinogenesis, mutagenesis and fertility

Women of child-bearing potential

Women of child-bearing potential should use appropriate contraceptive measures during treatment.

Fertility

There are no clinical data on fertility with the use of carvedilol/ivabradine.

Studies with carvedilol have shown impaired fertility in adult female rats. Studies in rats with ivabradine shown no effect on fertility in males and females.

Effects on ability to drive and use machines

Based on existing data with the individual components, the use of carvedilol/ivabradine fixed-dose combination may affect the ability to drive or use machinery.

Due to variability of individual reactions on carvedilol (such as dizziness, fatigue or decreased alertness), the ability to drive or operate machinery may be impaired. This is particularly true at the start of treatment, when the dose is increased, during the switch to a new preparation, or when taken together with alcohol.

Ivabradine may affect the patient’s ability to drive. Patients should be warned that ivabradine may cause transient luminous phenomena (consisting mainly of phosphenes). Luminous phenomena may occur in situations when there are sudden variations in light intensity, especially when driving at night. Ivabradine has no influence on the ability to use machines. However, in post-marketing experience, cases of impaired driving ability due to visual symptoms have been reported.

Adverse reactions


Summary of the safety profile

For carvedilol, the frequency of undesirable effects is not dose-dependent, with the exception of dizziness, visual disturbances and bradycardia.

For ivabradine, the most common adverse reactions, luminous phenomena (phosphenes) and bradycardia are dose-dependent and related to the pharmacological effect of the medicinal product.

Tabulated list of adverse reactions

The following undesirable effects have been observed during treatment with carvedilol and ivabradine given separately and ranked under the MedDRA classification by body system and under heading of frequency using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).

MedDRA
System Organ
Class
Undesirable effects Frequency
CarvedilolIvabradine
Infections and
infestations
Bronchitis Common-
Pneumonia Common-
Upper respiratory tract infectionsCommon-
Urinary tract infections Common-
Blood and
lymphatic system
disorders
Anaemia Common-
Eosinophilia- Uncommon
Thrombocytopenia Rare-
Leukopenia Very rare-
Immune system
disorders
Allergic reactions (hypersensitivity) Very rare-
Metabolism and
nutrition disorders
Hypercholesterolaemia Common-
Deterioration in glycaemic control
(hyperglycaemia or hypoglycaemia) in
patients with pre-existing diabetes
Common-
Diabetes mellitus Common-
Hyperuricaemia- Uncommon
Psychiatric
disorders
Depressive mood, depression Common-
Sleep disorders, nightmares Uncommon-
Confusion Uncommon-
Nervous system
disorders
Headache Very common Common
Dizziness Very common Common
Syncope UncommonUncommon
Presyncope Uncommon-
Paraesthesia Uncommon-
Eye disorders Luminous phenomena (phosphenes) - Very Common
Visual impairmentCommon Uncommon
Irritation of the eye Common-
Blurred vision- Common
Reduced lacrimation Common-
Diplopia- Uncommon
Ear and labyrinth
disorders
Vertigo- Uncommon
Cardiac disorders Heart failure Very common-
Bradycardia Common Common
Pulmonary oedema Common-
Oedema (including generalised and
peripheral oedema and swelling of the
genital area and feet, hypervolaemia and
fluid retention)
Common-
AV 1st degree block (ECG prolonged PQ
interval)
- Common
Ventricular extrasystoles- Common
Atrial fibrillation- Common
Angina pectoris Uncommon-
Palpitations- Uncommon
Supraventricular extrasystoles- Uncommon
AV-block Uncommon-
AV 2nd degree block- Very Rare
AV 3rd degree block- Very Rare
Sick sinus syndrome- Very Rare
Vascular disorders HypotensionVery common Uncommon
(possibly related
to bradycardia)
Postural hypotension Common-
Disturbances of peripheral circulation (cold
extremities, PVD, exacerbation of
intermittent claudication and Raynauds
phenomenon)
Common-
Uncontrolled blood pressure- Common
Respiratory,
thoracic and
mediastinal
disorders
DyspnoeaCommon Uncommon
Asthma in predisposed patients Common-
Nasal congestion Rare-
Wheezing Rare-
Gastrointestinal
disorders
Nausea Common Uncommon
Diarrhoea Common Uncommon
Abdominal pain Common Uncommon*
Vomiting Common-
Dyspepsia Common-
Constipation Uncommon Uncommon
Dry mouth Rare-
Skin and
subcutaneous tissue
disorders
Skin reactions (such as allergic exanthema,
dermatitis, urticaria, pruritus and increased
sweating)
Uncommon-
Reactions similar to lichen planus,
psoriasis or psoriasiform exanthema
(occurring several weeks up to years after
the start of treatment). Existing lesions may
worsen.
Uncommon-
Alopecia Uncommon-
Angioedema- Uncommon
Rash- Uncommon
Erythema- Rare
Pruritus- Rare
Urticaria- Rare
Severe skin reactions (such as erythema
multiforme, Stevens-Johnson syndrome,
toxic epidermal necrolysis)
Very rare-
Musculoskeletal
and connective
tissue disorders
Pain in extremities Common-
Gout Common -
Muscle spasms- Uncommon
Renal and urinary
disorders
Renal failure and renal function
abnormality in patients with diffuse
vascular disease and/or underlying renal
insufficiency
Common-
Micturition disorders Common-
Urinary incontinence in women Very rare-
General disorders
and administration
site conditions
Asthenia, fatigue Very common Uncommon
Pain Common-
Malaise (possibly related to bradycardia) - Rare
Investigations Weight gainCommon-
Blood creatinine increased- Uncommon
ECG prolonged QT interval- Uncommon
Increase in the transaminases ALT, AST
and GGT
Very rare-
Reproductive
system and breast
disorders
Impotence, erectile dysfunction Uncommon-

* Frequency calculated from clinical trials for adverse events detected from spontaneous report.

Description of selected adverse reactions

Carvedilol

Dizziness, syncope, headache and debility are generally mild and are more likely to occur at the start of treatment.

Cardiac failure is an event commonly reported both in patients treated with placebo and in patients treated with carvedilol (14.5% and 15.4% respectively, in patients with left ventricular dysfunction following acute myocardial infarction).

A reversible deterioration in renal function has been observed during treatment with carvedilol in patients with chronic cardiac insufficiency with low blood pressure, ischaemic heart disease and diffuse vascular disease and/or basal renal insufficiency.

Non-selective beta-blockers in particular may cause latent diabetes to become manifest, manifest diabetes to be aggravated and blood glucose control to be impaired. The glucose balance may also be slightly upset during treatment with carvedilol, but this does not happen often.

Carvedilol may cause urinary incontinence in women. The problem is resolved once treatment is discontinued.

Ivabradine

Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightness in a limited area of the visual field. They are usually triggered by sudden variations in light intensity. Phosphenes may also be described as a halo, image decomposition (stroboscopic or kaleidoscopic effects), coloured bright lights, or multiple images (retinal persistency). The onset of phosphenes is generally within the first two months of treatment after which they may occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity. All phosphenes resolved during or after treatment, of which a majority (77.5%) resolved during treatment. Fewer than 1% of patients changed their daily routine or discontinued the treatment in relation with phosphenes.

Bradycardia was reported by 3.3% of patients particularly within the first 2 to 3 months of treatment initiation. 0.5% of patients experienced a severe bradycardia below or equal to 40 bpm.

In the SIGNIFY study, atrial fibrillation was observed in 5.3% of patients taking ivabradine compared to 3.8% in the placebo group. In a pooled analysis of all the Phase II/III double blind controlled clinical trials with a duration of at least 3 months including more than 40,000 patients, the incidence of atrial fibrillation was 4.86% in ivabradine treated patients compared to 4.08% in controls, corresponding to a hazard ratio of 1.26, 95% CI [1.15-1.39].

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.